|
Post by dreamboatcruise on Jan 20, 2017 15:17:49 GMT -5
People just continue to post what everyone wants to hear, mindboggling. Really? I, for one, try my best to post what I hope is relevant, thoughtful and to the point of each discussion. Seems clear to me that most every contributor here tries to contribute some variation on that same theme. I'm happy with the fact the insight and attitude of each delivery, including yours, is all over the map. My intended strong suit is encouragement. What's yours? Just keep in mind that unsubstantiated speculation that gets caught in an echo chamber of "encouragement" could be encouraging people to make financial decisions that they should not be making. MNKD is a risky investment at this point. Even if they succeed ultimately, there could be so much dilution that even buying at these levels would generate a loss. Perhaps MNKD pulls a rabbit out of the hat and anyone in the stock right now is a big winner, but people certainly shouldn't be "encouraged" to speculate on MNKD based on some false consensus that "something big" is clearly about to happen. If the audience were limited to die hard MNKD "I'm holding til the end and willing to lose it all" and/or "It's like Vegas, I'm having fun, it's not my retirement", then the type of speculation and "encouragement" as started this thread might be harmless. But in a wider forum, which I think this is, "encouragement" without being put in context of "I'm throwing out some wishful idea in order to bolster spirits of shareholders" could convince someone to lose real money that they can't afford to lose. So I can't speak for kbrion, who you posed your question to, but for myself... I am neither here to pump or bash, encourage or discourage... I'm hear to keep up on real developments of MNKD and try to promote a balanced dialog that would make this board a good resource for people wanting to make serious investing decisions about whether to risk their real hard earned money.
|
|
|
Post by falconquest on Jan 20, 2017 16:24:07 GMT -5
Really? I, for one, try my best to post what I hope is relevant, thoughtful and to the point of each discussion. Seems clear to me that most every contributor here tries to contribute some variation on that same theme. I'm happy with the fact the insight and attitude of each delivery, including yours, is all over the map. My intended strong suit is encouragement. What's yours? Just keep in mind that unsubstantiated speculation that gets caught in an echo chamber of "encouragement" could be encouraging people to make financial decisions that they should not be making. MNKD is a risky investment at this point. Even if they succeed ultimately, there could be so much dilution that even buying at these levels would generate a loss. Perhaps MNKD pulls a rabbit out of the hat and anyone in the stock right now is a big winner, but people certainly shouldn't be "encouraged" to speculate on MNKD based on some false consensus that "something big" is clearly about to happen. If the audience were limited to die hard MNKD "I'm holding til the end and willing to lose it all" and/or "It's like Vegas, I'm having fun, it's not my retirement", then the type of speculation and "encouragement" as started this thread might be harmless. But in a wider forum, which I think this is, "encouragement" without being put in context of "I'm throwing out some wishful idea in order to bolster spirits of shareholders" could convince someone to lose real money that they can't afford to lose. So I can't speak for kbrion, who you posed your question to, but for myself... I am neither here to pump or bash, encourage or discourage... I'm hear to keep up on real developments of MNKD and try to promote a balanced dialog that would make this board a good resource for people wanting to make serious investing decisions about whether to risk their real hard earned money. Well said dream. People buy shares as an investment because they expect a higher rate of return than their bank. Investors expect a return on their money not promise after promise that is supposed to make us feel better. We have been doing that for years here. The goal is always just a little ahead. Problem is, we never get there. We have an outstanding product, we have a management team that regardless of your opinion of them, is working very hard to take the necessary steps to promote the product. But the bottom line is.....investors demand a return. It isn't about loving the company or it's product (although some investors may if they also use it) it's about MAKING MONEY! So far we have done lots of stuff except MAKE MONEY. It's okay to be positive but you also have to be realistic and not falsely pump or bash the company. Realistically things are looking rather bleak right now.
|
|
|
Post by dreamboatcruise on Jan 20, 2017 17:19:15 GMT -5
falconquestI suspect the ship has sailed on me making money... I'd be happy to have less loss.
|
|
|
Post by zuegirdor on Jan 20, 2017 17:20:18 GMT -5
|
|
|
Post by orlon on Jan 20, 2017 17:39:23 GMT -5
I have to smile when I read an optimistic post about 'big things just around the corner.' When you've held on to this stock as long as some of us have, you begin to realize there are no corners in the round room.
|
|
|
Post by afrezzamiracle on Jan 20, 2017 17:42:46 GMT -5
We took the product back around a year ago and we are selling essentially NONE at this point. I want sales, and I want them NOW. And we won't sell any until we advertise. Let's get started NOW, because "too late" is almost here!
|
|
|
Post by zuegirdor on Jan 20, 2017 18:20:39 GMT -5
Hate to sound like a Debbie downer (if you want my pollyanna imperspnation, go here mnkd.proboards.com/thread/7072/management-failed-cold-hard-reality?page=1&scrollTo=92615)But its not as simple as sales and ads to chase sales. I am just an eyelash parasite on the gnat on the wall of the 4th stall in the bathroom on the 6th floor of the Tower of Commerce on Excrapulon 7 but I say MNKD knows something that only users know. And that is that it is very hard for endos to explain how to use Afrezza. It is likely that there is a profile of a subset of diabetics, perhaps a small subset, that endos can trust will have the committment and , dare I say it, SMARTS to figure out how its supposed to work as a patients only inuslin. And once these users figure it out, they best hope its covered by insurance because, unless they are eating low carb, they will need, as other posters here have noted, more than a standard 90 cartridge pack. Maybe three packs. But Pollyanna thinks that some users and managers and maybe some investors suspect there is a larger strategy at play. What if the easiest (if not the best?) way to use Afrezza involves the new Artificial Pancreas as has also been overheard in talk of the men's room? That could change everything. Afrezza would no longer be for just this subset of motivated intelligent users. If this combination of the Artificial Pancreas and Afrezza were truly as easy as it seems it may be, then things might change fast. Granted this extends the time line for Afrezza success. But think how important the success of Afrezza could be to the success of the Artificial Pancreas. Makes you think.
|
|
|
Post by sayhey24 on Jan 20, 2017 19:16:04 GMT -5
Hate to sound like a Debbie downer (if you want my pollyanna imperspnation, go here mnkd.proboards.com/thread/7072/management-failed-cold-hard-reality?page=1&scrollTo=92615)But its not as simple as sales and ads to chase sales. I am just an eyelash parasite on the gnat on the wall of the 4th stall in the bathroom on the 6th floor of the Tower of Commerce on Excrapulon 7 but I say MNKD knows something that only users know. And that is that it is very hard for endos to explain how to use Afrezza. It is likely that there is a profile of a subset of diabetics, perhaps a small subset, that endos can trust will have the committment and , dare I say it, SMARTS to figure out how its supposed to work as a patients only inuslin. And once these users figure it out, they best hope its covered by insurance because, unless they are eating low carb, they will need, as other posters here have noted, more than a standard 90 cartridge pack. Maybe three packs. But Pollyanna thinks that some users and managers and maybe some investors suspect there is a larger strategy at play. What if the easiest (if not the best?) way to use Afrezza involves the new Artificial Pancreas as has also been overheard in talk of the men's room? That could change everything. Afrezza would no longer be for just this subset of motivated intelligent users. If this combination of the Artificial Pancreas and Afrezza were truly as easy as it seems it may be, then things might change fast. Granted this extends the time line for Afrezza success. But think how important the success of Afrezza could be to the success of the Artificial Pancreas. Makes you think. I for one hope there is a bigger hidden strategy because selling a "faster than RAA insulin which is inhaled" which according to the label does not give you better control is not going to work. More over afrezza is not anything like an RAA. An RAA "kind-of" provides phase 2 insulin release. Afrezza on the first puff provides phase 1 insulin release. That is night and day from an RAA. It is such a different product. If an hour later they take a second puff afrezza is then providing a true phase 2 release. By providing Phase 1 and phase 2 afrezza provides near-real pancreatic function. Now, go talk to your average endo about this. Most endos have no idea what "first phase insulin" even means. They only know what the drug companies have brainwashed them about while many times using very questionable studies. It would be an interesting survey to call endo's and ask them what "first phase insulin" is. I wonder if Mike has done that because that would be a great place to start. Now if you have a near-real pancreas, why do you need an AP, Tresiba is looking pretty good and it is a lot less work to maintain fasting BG levels, cheaper too.
|
|
|
Post by nylefty on Jan 20, 2017 19:29:55 GMT -5
We took the product back around a year ago and we are selling essentially NONE at this point. I want sales, and I want them NOW. And we won't sell any until we advertise. Let's get started NOW, because "too late" is almost here! "Essentially none?" Actually, as of a week ago we had 35,817 sales. The main problem is renewals...and renewals are low because most patients don't know how to use Afrezza. Advertising won't fix that....label changes and doctor education will.
|
|
|
Post by mnholdem on Jan 20, 2017 19:38:25 GMT -5
The 4th stall? So you're the guy who left the toilet seat up! The new 4-, 8- and 12-unit titration packs will help dispel the mistaken belief that patients typically "need more" units than RAA insulin. Sample packs have consisted of 4-unit cartridges since Afrezza first launched. Every patient is different, so offering only a small 4-unit cartridge package AND a lousy instruction for doctors to train titration of Afrezza to their patients was incredibly stupid, IMO. The good news is that MannKind has addressed Sanofi's blunder by releasing a better choice of packages for initial titration. Have the instructions for titration been fixed or will doctor & patient continue to be baffled about how much Afrezza is required? I'd luv to get my hands on the marketing literature. Until the FDA rules on label changes, MannKind reps will be handcuffed in many ways related to what they can say, verbally and within their literature. There are times that I wonder what this company has been doing for ten years that these issues caught them as a major surprise. It doesn't appear that market testing was a high priority for them, does it? Still, it would appear that progress is being made from lessons learned the hard way. --- Word on the street is that MannKind is beginning sales training of the new hires beginning next week.
|
|
dang
Newbie
Posts: 20
|
Post by dang on Jan 20, 2017 20:44:08 GMT -5
Stock options are part of the "package" that is basically required to hire professionals now a days.
As far as longs go, I'm about as long as you can be and I still have faith that something good may still happen...
|
|
|
Post by sayhey24 on Jan 20, 2017 20:51:21 GMT -5
The 4th stall? So you're the guy who left the toilet seat up! The new 4-, 8- and 12-unit titration packs will help dispel the mistaken belief that patients typically "need more" units than RAA insulin. Sample packs have consisted of 4-unit cartridges since Afrezza first launched. Every patient is different, so offering only a small 4-unit cartridge package AND a lousy instruction for doctors to train titration of Afrezza to their patients was incredibly stupid, IMO. The good news is that MannKind has addressed Sanofi's blunder by releasing a better choice of packages for initial titration. Have the instructions for titration been fixed or will doctor & patient continue to be baffled about how much Afrezza is required? I'd luv to get my hands on the marketing literature. Until the FDA rules on label changes, MannKind reps will be handcuffed in many ways related to what they can say, verbally and within their literature. There are times that I wonder what this company has been doing for ten years that these issues caught them as a major surprise. It doesn't appear that market testing was a high priority for them, does it? Still, it would appear that progress is being made from lessons learned the hard way. --- Word on the street is that MannKind is beginning sales training of the new hires beginning next week. Wow, I would like to attend that training or at least review the training materials. I sure hope they start with your post on Blood Sugar 101 and make sure they understand how the liver, gut, pancreas, etc work and how both the liver and pancreas are state machines which work in harmony. Then they show how afrezza mimics phase 1 release.
|
|
|
Post by falconquest on Jan 20, 2017 21:59:32 GMT -5
Every new patient ought to be urged to watch the videos from afrezzauser. He experimented with dosages until he dialed in what works for him. I think Afrezza is so effective that it takes a paradigm shift to understand it.
|
|
|
Post by tchalaa on Jan 21, 2017 7:04:18 GMT -5
1- Increasing insurance coverage;
2- DTC expected to be in 2H2017; 3- Label change to"Ulra-Rapid" expected to be in 3Q2017;
4- Increase TRx I project it to be in 4Q2017
|
|
|
Post by pguererro on Jan 21, 2017 8:32:13 GMT -5
The stock options are a great plus for the new employees (and remember everyone in the sales force is technically a new employee to mannkind from the 70% that were retained from the touchpoint contract to the new hires brought on board to get to a sales force of around 90) however, the salaries are very competitive from an industry standpoint and the bonuses if you reach your goals are actually much larger than industry standards. Just an FYI
|
|